Loading...
Thumbnail Image
Publication

Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis

McCormack, Lindsay
Ponce, Joseph
Chatterjee, Avik
Tan, Jennifer K.
Embargo Expiration Date
Link to Full Text
Abstract

Hyperhidrosis occurs when sweating is excessive for thermoregulatory purposes, which may result in decreased quality of life and emotional stress for patients.Classified as primary and secondary, secondary hyperhidrosis is often related to an underlying cause. Certain medications have been reported to induce hyperhidrosis, including selective serotonin reuptake inhibitors, tricyclic antidepressants, and opioid agonists. We present the case of a woman with a history of opioid use disorder who experienced hyperhidrosis in the setting of partial opioid agonist and opioid antagonist therapy (buprenorphine-naloxone), who was treated successfully with oral oxybutynin 5 mg daily.

Source

McCormack L, Ponce J, Chatterjee A, Tan JK. Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis. JAAD Case Rep. 2021 Jan 11;10:22-24. doi: 10.1016/j.jdcr.2020.12.031. PMID: 33732840; PMCID: PMC7941000. Link to article on publisher's site

Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1016/j.jdcr.2020.12.031
PubMed ID
33732840
Other Identifiers
Notes
Funding and Acknowledgements
Corresponding Author
Related Resources
Related Resources
Repository Citation
Rights
Copyright © 2021 by the American Academy of Dermatology, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).